Suppr超能文献

通过《健康中国行动(2019—2030年)》指导结核病防治工作

Guiding Tuberculosis Control Through the Healthy China Initiative 2019-2030.

作者信息

Zhang Hui, Liu Xiaoqiu, Xu Caihong, Hu Dongmei, Li Xue, Li Tao, Zhao Yanlin, Chen Mingting, Liu Jianjun

机构信息

National Center for Tuberculosis Control and Prevention, China CDC, Beijing, China.

出版信息

China CDC Wkly. 2020 Dec 4;2(49):948-950. doi: 10.46234/ccdcw2020.236.

Abstract

Tuberculosis (TB) is a global public health problem, especially in China. China has the third largest TB burden in the world with nearly 0.9 million new TB cases emerging annually. Despite impressive achievements, China still faces many challenges in TB control that threaten further progress and the ability to meet the targets of the End TB strategy if not addressed. On July 15, 2019, the State Council of China issued Healthy China Initiative 2019-2030, which proposed 15 special campaigns including the Tuberculosis Control Action to guide the way for China's TB prevention and control. This article introduces the current status of TB in China, achievements reached so far, and challenges remaining and interprets the targets and strategies from the individual, society, and government level in the Tuberculosis Control Action.

摘要

结核病是一个全球性的公共卫生问题,在中国尤为如此。中国的结核病负担位居世界第三,每年新增近90万例结核病病例。尽管取得了令人瞩目的成就,但中国在结核病防控方面仍面临诸多挑战,如果不加以解决,这些挑战将威胁到进一步的进展以及实现终结结核病战略目标的能力。2019年7月15日,中国国务院发布了《健康中国行动(2019—2030年)》,其中提出了包括结核病防治行动在内的15项专项行动,为中国的结核病预防和控制指明了方向。本文介绍了中国结核病的现状、迄今取得的成就、仍然存在的挑战,并从个人、社会和政府层面解读了结核病防治行动中的目标和策略。

相似文献

1
Guiding Tuberculosis Control Through the Healthy China Initiative 2019-2030.
China CDC Wkly. 2020 Dec 4;2(49):948-950. doi: 10.46234/ccdcw2020.236.
3
Roadmap for ending TB in China by 2035: The challenges and strategies.
Biosci Trends. 2024 Mar 19;18(1):11-20. doi: 10.5582/bst.2023.01325. Epub 2024 Feb 8.
4
[Tuberculosis in Asia].
Kekkaku. 2002 Oct;77(10):693-7.
5
Tuberculosis detection and the challenges of integrated care in rural China: A cross-sectional standardized patient study.
PLoS Med. 2017 Oct 17;14(10):e1002405. doi: 10.1371/journal.pmed.1002405. eCollection 2017 Oct.
7
Multi-source financing for tuberculosis treatment in China: key issues and challenges.
Infect Dis Poverty. 2021 Mar 10;10(1):17. doi: 10.1186/s40249-021-00809-4.
8
[China's countermeasures in the context of Global Tuberculosis Prevention Action].
Zhonghua Jie He He Hu Xi Za Zhi. 2022 Mar 12;45(3):308-312. doi: 10.3760/cma.j.cn112147-20210722-00520.
9
China's unique role in the field of global health.
Glob Health J. 2019 Dec;3(4):98-101. doi: 10.1016/j.glohj.2019.11.004. Epub 2019 Nov 25.

引用本文的文献

8
Drug Resistance and Molecular Characteristics of : A Single Center Experience.
J Pers Med. 2022 Dec 19;12(12):2088. doi: 10.3390/jpm12122088.

本文引用的文献

2
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling.
PLoS Med. 2016 Oct 25;13(10):e1002152. doi: 10.1371/journal.pmed.1002152. eCollection 2016 Oct.
3
Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data.
Lancet. 2014 Jun 14;383(9934):2057-2064. doi: 10.1016/S0140-6736(13)62639-2. Epub 2014 Mar 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验